— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
— Published date: 1/14/2026
Value Proposition: Method and composition to potently neutralize EEEV infection.
Technology Description
Researchers at Washington University in St. Louis have developed very low-density lipoprotein receptor (VLDLR) soluble decoy receptors with potent inhibitory acti…
— Published date: 1/14/2026
Value Proposition: First antiviral treatment that uses soluble receptors to treat yellow fever.
Technology Description
Researchers at Washington University in St. Louis have developed new soluble receptor decoy Fc-fusion protein inhibitors for the treatment of yellow f…
— Published date: 1/14/2026
Value Proposition: Decoy receptor therapeutic that can treat multiple VEEV subtypes by blocking VEEV entry and infection.
Technology Description
Researchers at Washington University in St. Louis have developed a decoy Ldlrad3-D1-Fc protein for prevention of treatment o…
— Published date: 1/14/2026
Value Proposition: Fusion protein that can be used to prevent and treat arthritogenic alphavirus infections.
Technology Description
Researchers at Washington University in St. Louis have identified MXRA8 (matrix remodeling associated protein 8) protein as a key recepto…
— Published date: 9/18/2025
Value Proposition: Single chain RANK ligand that can selectively inhibit pathological bone loss.
Technology Description
Researchers at Washington University in St. Louis have developed a genetically engineered mutant RANKL protein that prevents bone loss by selective…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
